Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
8.60
-0.32 (-3.59%)
At close: Nov 5, 2026, 4:00 PM EST
8.39
-0.21 (-2.44%)
Pre-market: Nov 6, 2026, 5:49 AM EST
Capricor Therapeutics Market Cap
Capricor Therapeutics has a market cap or net worth of $500 million as of November 5, 2026. It is the 14,300th most valuable company in the world and the 2,698th biggest in the United States. Its market cap has increased by 80.50% in one year.
Market Cap
500.00M
Enterprise Value
353.11M
1-Year Change
80.50%
Global Rank
Country Rank
#2,698 United States
Category
ChartMarket Cap Chart
Since May 13, 2008, Capricor Therapeutics's market cap has increased from $130.10M to $500.00M, an increase of 284.32%. That is a compound annual growth rate of 7.55%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 5, 2026 | 500.00M | -62.10% |
| Dec 31, 2025 | 1.32B | 110.26% |
| Dec 31, 2024 | 627.50M | 316.67% |
| Dec 29, 2023 | 150.60M | 54.62% |
| Dec 30, 2022 | 97.40M | 37.57% |
| Dec 31, 2021 | 70.80M | 1.00% |
| Dec 31, 2020 | 70.10M | 1,198.15% |
| Dec 31, 2019 | 5.40M | -57.48% |
| Dec 31, 2018 | 12.70M | -68.72% |
| Dec 29, 2017 | 40.60M | -28.65% |
| Dec 30, 2016 | 56.90M | 13.80% |
| Dec 31, 2015 | 50.00M | 13.90% |
| Dec 31, 2014 | 43.90M | 1,467.86% |
| Dec 31, 2013 | 2.80M | 27.27% |
| Dec 31, 2012 | 2.20M | -89.91% |
| Dec 30, 2011 | 21.80M | 1.40% |
| Dec 31, 2010 | 21.50M | -36.39% |
| Dec 31, 2009 | 33.80M | 38.52% |
| Dec 31, 2008 | 24.40M | -81.25% |
| May 13, 2008 | 130.10M | - |
View and export this data all the way back to 2008. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| REGENXBIO | 506.98M |
| Faeth Therapeutics | 501.95M |
| Indaptus Therapeutics | 492.23M |
| CytomX Therapeutics | 491.36M |
| Arvinas | 476.34M |
| MiMedx Group | 475.72M |
| Monopar Therapeutics | 473.41M |
| Ovid Therapeutics | 470.67M |